Day: December 14, 2022
Abstract highlights promising results from PURE EP™ study at premier Asia-Pacific Heart Rhythm Society Conference
Westport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that its PURE EP™ System was featured in an abstract presentation during the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore.
Results from the randomized study reveal the PURE EP™ System’s potential to promote shorter procedural times and higher cost savings during catheter ablations. The study enrolled 29 patients with non-paroxysmal AF with post-ablation...
DriveItAway Holdings, Inc. Partners with Legacy Auto Credit Launching Vehicle Subscriptions in Canada
Written by Customer Service on . Posted in Public Companies.
Legacy Auto Credit, headquartered in Ontario, Canada partners with DriveItAway to launch an app-based subscription to ownership program in Canada
“We are proud to welcome Legacy Auto Credit as a key partner for DriveItAway’s unique subscription to ownership platform to expand our service into Canada” John F. Possumato, Founder & CEO, DriveItAway Holdings, Inc.
PHILADELPHIA and Ontario, Canada, Dec. 14, 2022 (GLOBE NEWSWIRE) — DriveItAway Holdings, Inc. (“DriveItAway”), (OTC Marketplace: DWAY), an industry leader in automotive industry new mobility platforms with its unique subscription to purchase technology, is excited to announce its partnership with Legacy Auto Credit, specialists in helping people who are credit challenged drive a new or used vehicle, based in Ontario, Canada.
“For decades Legacy Auto Credit has helped...
European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer
Written by Customer Service on . Posted in Public Companies.
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the European Commission (EC) has designated upifitamab rilsodotin (UpRi) as an orphan medicinal product for the treatment of ovarian cancer. UpRi is Mersana’s first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that is designed to enable a high drug-to-antibody ratio and controlled bystander effect.
“Receiving this orphan designation in the European Union is an important regulatory milestone for Mersana as we seek to expedite UpRi’s global development,” said Anna Protopapas, President and Chief Executive Officer of...
Kratos Receives Initial $30 Million Funding on Potential $250 Million C5ISR Single Award Production Program
Written by Customer Service on . Posted in Public Companies.
SAN DIEGO, Dec. 14, 2022 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has received the initial $30 million in funding on a potential $250 million Command, Control, Communication, Computing, Combat System Intelligence, Surveillance and Reconnaissance (C5ISR) program. The new contract is single award to Kratos. Kratos is a technology company in the National Security market and a leading provider of systems, subsystems, components and solutions for mission critical programs, including in the unmanned aerial drone, hypersonic, space, satellite communication, propulsion system, cyber warfare and microwave electronic areas. Work under this new program award will be performed at secure Kratos engineering and manufacturing facilities....
SoHum Living Soils® Receives OIM Certification of Registration
Written by Customer Service on . Posted in Public Companies.
This Registration Ensures SoHum Products are Compliant With all California Regulations for Organic Materials
LAKEWOOD, CO, Dec. 14, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – American Cannabis Company, Inc. (OTCQB: AMMJ) (“ACC” or “Company”), a business-to-business cannabis consulting solutions provider and licensed owner operator, is pleased to announce that our subsidiary company SoHum Living Soils® has received Organic Input Material (OIM) certification from the California Department of Food and Agriculture. This certification ensures that SoHum products are compliant with all California regulations for organic materials, and it establishes SoHum as a premium living soil product.
“We’re extremely excited about receiving this certification. SoHum Living Soils® is dedicated to clean green organic cultivation, and compliance with...
Applied Digital Announces Groundbreaking of High Performance Computing Facility in Jamestown, North Dakota
Written by Customer Service on . Posted in Public Companies.
The Company’s Project in North Dakota Supports Applied Digital’s Expansion and Market Demand for Hosting High-Performance Computing (HPC) Applications
DALLAS, Dec. 14, 2022 (GLOBE NEWSWIRE) — Applied Digital Corporation (Nasdaq: APLD) (“Applied Digital” or the “Company”), announced today the groundbreaking of its latest specialized processing center, a five-megawatt (“MW”) facility next to the Company’s currently operating 100-MW hosting facility in Jamestown, North Dakota. This separate and unique building, designed and purpose-built for Graphics Processing Units (“GPUs”), will sit separate from the Company’s current buildings and plans to host more traditional high performance computing (“HPC”) applications, such as natural language processing, machine learning, and additional HPC developments.
The new 16,382-square foot building...
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial
Written by Customer Service on . Posted in Public Companies.
Objective Response Rate (ORR) by Central Review Achieved in Each Cohort at Interim Efficacy Analysis that Exceeded the Futility Threshold
Enrollment Continues Ahead of Schedule; Next Interim Analysis Expected in mid-2023 with Full Accrual Now Expected Before the End of 2023
Arbitration Decision Expected in 1Q 2023 has Potential to Increase Cash Runway
SAN DIEGO, Dec. 14, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the IDMC for the ongoing ENVASARC Phase 2 pivotal trial recommended continued accrual as planned in both cohorts: single agent envafolimab and envafolimab in...
Columbia Financial, Inc. Announces Fifth Stock Repurchase Program
Written by Customer Service on . Posted in Public Companies.
FAIR LAWN, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) — Columbia Financial, Inc. (Nasdaq: CLBK) (the “Company”), the holding company for Columbia Bank and Freehold Bank, today announced that the Company’s Board of Directors has authorized a new stock repurchase program to acquire up to 3,000,000 shares, or approximately 2.7%, of the Company’s currently issued and outstanding common stock, commencing upon the completion of the Company’s existing stock repurchase program.
On December 6, 2021, the Company announced its fourth stock repurchase program which authorized the purchase of up to 5,000,000 shares. Under this previously announced program, 4,311,566 shares of common stock have been repurchased at a cost of $90.6 million, or $20.99 per share. As of December 12, 2022, there are 688,434 shares remaining to be repurchased under...
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)
Written by Customer Service on . Posted in Public Companies.
Multiple Myeloma – 85% overall response rate (71% CR/sCR) for NXC-201 at therapeutic dose in an ongoing Phase 1b study in 20 relapsed/refractory patients as of June 27, 2022 data cutoff (Haematologica https://doi.org/10.3324/haematol.2022.281628)
AL Amyloidosis – 100% complete responses, 100% organ response rate for NXC-201 in 4 relapsed/refractory patients (Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637)
Potential first and only out-patient CAR-T: Low-grade CRS duration of median 2 days (range, 1-5 days) at NXC-201 therapeutic dose
Immix Biopharma forms wholly- owned subsidiary Nexcella, Inc to develop NXC-201 and other CAR-T cell therapies for oncology and other diseasesLOS ANGELES, CA, Dec. 14, 2022 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or...
Mullen Automotive Partners with Loop Global to Deploy EV Charging Solutions, Including Public DC Fast Charging Network and Residential Offerings
Written by Customer Service on . Posted in Public Companies.
Mullen EV Charging Network
Public DC Charging and Residential Offerings Powered By LoopLoop to offer up to $300 million in available financing via its Loop-as-a-Service program to deploy Level 2 and Level 3 DC public charging stations across the Mullen Charging Network Powered By Loop
Mullen and Loop will provide turnkey, co-branded intelligent electric vehicle charging technology, accelerating the expansion of the charging infrastructure in the USA
BREA, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that it has entered into a definitive agreement with Loop Global Inc. (“Loop”), a full-service EV charging solution provider, to build the next generation of public...